Literature DB >> 24445062

Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis.

P C Goeminne1, T S Nawrot2, D Ruttens3, S Seys4, L J Dupont3.   

Abstract

INTRODUCTION: There is limited data on mortality and associated morbidity in non-cystic fibrosis bronchiectasis (NCFB). Our aim was to analyze the overall mortality for all newly diagnosed patients from June 2006 onwards and to evaluate risk factors for mortality in this cohort.
METHODS: 245 patients who had a new diagnosis of NCFB between June 2006 and October 2012 at the University Hospital of Leuven, Belgium, were included in the analysis. Death was analyzed until end of November 2013. All patients had chest HRCT scan confirming the presence of bronchiectatic lesions and had symptoms of chronic productive cough. Univariate and multivariate Cox proportional hazard survival regression analysis was used to estimate hazard ratios (HR) and their 95% confidence intervals (CI) of variables possibly predicting mortality.
RESULTS: Overall mortality in NCFB patients who had a median follow-up of 5.18 years was 20.4%. Patients with NCFB and associated chronic obstructive pulmonary disease (COPD) had a mortality of 55% in that period. Univariate analysis showed higher mortality according to age, gender, smoking history, Pseudomonas aeruginosa status, spirometry, radiological extent, total number of sputum bacteria and underlying etiology. Multivariate analysis showed significant higher mortality with increasing age (HR = 1.045; p = 0.004), with increasing number of lobes affected (HR = 1.53; p = 0.009) and when patients had COPD associated NCFB (HR = 2.12; p = 0.038). The majority of the 50 deaths were respiratory related (n = 29; 58%).
CONCLUSION: NCFB patients with associated COPD disease had the highest mortality rates compared to the other NCFB patients. Additional risk factors for lower survival were increasing age and number of lobes affected.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bronchiectasis; COPD; Chronic colonization; Mortality; Pseudomonas aeruginosa; Survival

Mesh:

Year:  2014        PMID: 24445062     DOI: 10.1016/j.rmed.2013.12.015

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  42 in total

Review 1.  Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis.

Authors:  Annemarie L Lee; Angela T Burge; Anne E Holland
Journal:  Cochrane Database Syst Rev       Date:  2017-09-27

Review 2.  Diagnosis and management of bronchiectasis.

Authors:  Maeve P Smith
Journal:  CMAJ       Date:  2017-06-19       Impact factor: 8.262

3.  Effect of airway Pseudomonas aeruginosa isolation and infection on steady-state bronchiectasis in Guangzhou, China.

Authors:  Wei-Jie Guan; Yong-Hua Gao; Gang Xu; Zhi-Ya Lin; Yan Tang; Hui-Min Li; Zhi-Min Li; Jin-Ping Zheng; Rong-Chang Chen; Nan-Shan Zhong
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

4.  Managing Bronchiectasis: 13 Years of Experience from Sputum to Lung Transplantation.

Authors:  Fatma Işıl Uzel; Sedat Altın; Esin Yentürk; Burak Uzel; Ali Cevat Kutluk; Esin Tuncay
Journal:  Turk Thorac J       Date:  2020-07

5.  Survival in Patients with Advanced Non-cystic Fibrosis Bronchiectasis Versus Cystic Fibrosis on the Waitlist for Lung Transplantation.

Authors:  Don Hayes; Benjamin T Kopp; Joseph D Tobias; Frederick W Woodley; Heidi M Mansour; Dmitry Tumin; Stephen E Kirkby
Journal:  Lung       Date:  2015-10-01       Impact factor: 2.584

6.  Mortality after Respiratory Isolation of Nontuberculous Mycobacteria. A Comparison of Patients Who Did and Did Not Meet Disease Criteria.

Authors:  Shannon A Novosad; Emily Henkle; Sean Schafer; Katrina Hedberg; Jennifer Ku; Sarah A R Siegel; Dongseok Choi; Christopher G Slatore; Kevin L Winthrop
Journal:  Ann Am Thorac Soc       Date:  2017-07

Review 7.  Biomarkers of progression of chronic obstructive pulmonary disease (COPD).

Authors:  Janet G Shaw; Annalicia Vaughan; Annette G Dent; Phoebe E O'Hare; Felicia Goh; Rayleen V Bowman; Kwun M Fong; Ian A Yang
Journal:  J Thorac Dis       Date:  2014-11       Impact factor: 2.895

8.  Prognostic Factors in Adult Patients with Non-Cystic Fibrosis Bronchiectasis.

Authors:  Betina Charvet Machado; Patrícia Santos Jacques; Louise Piva Penteado; Paulo de Tarso Roth Dalcin
Journal:  Lung       Date:  2018-09-25       Impact factor: 2.584

9.  Distance-saturation product of the 6-minute walk test predicts mortality of patients with non-cystic fibrosis bronchiectasis.

Authors:  Meng-Heng Hsieh; Yueh-Fu Fang; Fu-Tsai Chung; Chung-Shu Lee; Yu-Chen Chang; Yuan-Zhang Liu; Cheng-Hsien Wu; Horng-Chyuan Lin
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

10.  Managing bronchiectasis in adults in primary care: a clinical update.

Authors:  Kevin Gruffydd-Jones; Duncan Keeley; James Wildgoose; Adam Hill
Journal:  Br J Gen Pract       Date:  2021-03-26       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.